{"id":"hepatitis-b-adjuvanted-vaccine","safety":{"commonSideEffects":[{"rate":"30-40","effect":"Injection site pain"},{"rate":"10-20","effect":"Injection site redness"},{"rate":"10-20","effect":"Injection site swelling"},{"rate":"10-20","effect":"Fatigue"},{"rate":"5-15","effect":"Myalgia"},{"rate":"5-15","effect":"Headache"},{"rate":"1-5","effect":"Fever"}]},"_chembl":null,"_dailymed":{"setId":"d61c7f99-438b-4cac-ae10-997ff4c0fd1f","title":"HEPLISAV-B (HEPATITIS B VACCINE (RECOMBINANT) ADJUVANTED) INJECTION, SOLUTION [DYNAVAX TECHNOLOGIES CORPORATION]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains recombinant hepatitis B surface antigen (HBsAg) combined with an adjuvant system (AS04, containing aluminum hydroxide and MPL) that amplifies both humoral and cell-mediated immune responses. The adjuvant enhances antigen presentation to B and T cells, resulting in stronger and more durable antibody production and memory immune responses compared to non-adjuvanted formulations. This leads to protective immunity against hepatitis B infection.","oneSentence":"This vaccine stimulates the immune system to produce antibodies and cellular immunity against hepatitis B virus by presenting hepatitis B surface antigen with an adjuvant that enhances the immune response.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:15:10.971Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of hepatitis B infection in adults"},{"name":"Prevention of hepatitis B infection in adolescents and children"}]},"trialDetails":[{"nctId":"NCT03866187","phase":"PHASE1, PHASE2","title":"Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2019-03-28","conditions":"Hepatitis B, Chronic","enrollment":236},{"nctId":"NCT06507605","phase":"PHASE1","title":"Dose-Escalating Study of Pfs230D1 in Combination With R21 in Matrix-M in African Adults","status":"COMPLETED","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2024-08-30","conditions":"Prevention of Malaria Transmission and Clinical Malaria","enrollment":240},{"nctId":"NCT05170399","phase":"PHASE4","title":"Vaccine Responses in Patients With B Cell Malignancies","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2022-09-14","conditions":"Lymphoma","enrollment":500},{"nctId":"NCT05561673","phase":"PHASE1","title":"A Study on the Safety and Immune Response of AS37 Together With Hepatitis B Antigen in Adults Aged 18-45 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-10-04","conditions":"Hepatitis B","enrollment":122},{"nctId":"NCT05276297","phase":"PHASE2","title":"A Study on the Safety, Efficacy and Immune Response Following Sequential Treatment With an Anti-sense Oligonucleotide Against Chronic Hepatitis B (CHB) and Chronic Hepatitis B Targeted Immunotherapy (CHB-TI) in CHB Patients Receiving Nucleos(t)Ide Analogue (NA) Therapy","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-03-22","conditions":"Hepatitis B, Chronic","enrollment":174},{"nctId":"NCT04674462","phase":"PHASE4","title":"Understanding Poor Vaccine Responses to Hepatitis B Vaccination","status":"ACTIVE_NOT_RECRUITING","sponsor":"NYU Langone Health","startDate":"2022-07-07","conditions":"Vaccine Reaction","enrollment":101},{"nctId":"NCT04684914","phase":"PHASE2","title":"HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB)","status":"TERMINATED","sponsor":"Altimmune, Inc.","startDate":"2020-12-26","conditions":"Hepatitis B, Chronic","enrollment":87},{"nctId":"NCT07147400","phase":"PHASE2","title":"Pfs230D1 + R21 in Matrix-M1 in African School Children and Adults","status":"RECRUITING","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2025-08-22","conditions":"Prevention of Malaria Transmission and Clinical Malaria","enrollment":1200},{"nctId":"NCT04843852","phase":"PHASE1","title":"TLR-9 Adjuvanted Vaccination for Chronic Hepatitis B","status":"RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2025-10-16","conditions":"Hepatitis B, Chronic Hepatitis B","enrollment":10},{"nctId":"NCT05155579","phase":"PHASE1","title":"Assessment of Safety and Immunogenicity of a Single Vial Presentation of R21/Matrix-M and Co-Administration With EPI Vaccines","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2022-05-14","conditions":"Malaria","enrollment":593},{"nctId":"NCT03312699","phase":"PHASE1","title":"Effects of Aging on Primary and Secondary Vaccine Responses","status":"COMPLETED","sponsor":"Stanford University","startDate":"2017-09-19","conditions":"Influenza, Hepatitis A, Typhoid","enrollment":54},{"nctId":"NCT03039790","phase":"PHASE2","title":"Long-Term Immunogenicity of the Norovirus GI.1/GII.4 Bivalent Virus-like Particle (VLP) Vaccine (NoV Vaccine) in Adults","status":"COMPLETED","sponsor":"Takeda","startDate":"2017-02-21","conditions":"Healthy Volunteers, Norovirus","enrollment":528},{"nctId":"NCT03685708","phase":"PHASE2","title":"HEPLISAV-B Hepatitis B Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's-Tyrosine Kinase Inhibitor (BTK-I)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2018-12-07","conditions":"Hepatitis, Safety and Tolerability","enrollment":78},{"nctId":"NCT03410953","phase":"PHASE4","title":"Vaccination Adjuved Against Hepatitis B in SNS Workers Typed as no Responders to Conventional Vaccines","status":"COMPLETED","sponsor":"Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León","startDate":"2018-04-13","conditions":"Hepatitis B, Hepatitis, Hepatitis, Viral, Human","enrollment":67},{"nctId":"NCT00985426","phase":"PHASE3","title":"Comparing Safety and Immunogenicity of HEPLISAV-B® to Engerix-B® in Chronic Kidney Disease (CKD) Patients","status":"COMPLETED","sponsor":"Dynavax Technologies Corporation","startDate":"2009-09","conditions":"Chronic Kidney Disease","enrollment":521},{"nctId":"NCT04385524","phase":"NA","title":"Use of Dynavax Heplisav B in Healthcare Workers Previously Vaccinated With 3-dose Vaccine Who Failed to Demonstrate Seroprotection","status":"WITHDRAWN","sponsor":"University of Louisville","startDate":"2020-06-01","conditions":"Hepatitis B Virus","enrollment":""},{"nctId":"NCT04515368","phase":"NA","title":"A Pilot Clinical Study of PET Scanning in Evaluation of Vaccine Reactogenicity","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2016-06-10","conditions":"Positron-Emission Tomography, Immunization Reaction","enrollment":54},{"nctId":"NCT01951677","phase":"PHASE1","title":"Safety and Efficacy Study of Adjuvanted Prophylactic Hepatitis B Vaccine","status":"COMPLETED","sponsor":"Vaxine Pty Ltd","startDate":"2013-07","conditions":"Exposure to Hepatitis B Virus","enrollment":240},{"nctId":"NCT02117934","phase":"PHASE3","title":"Safety and Immunogenicity Study of the Hepatitis B Vaccine, HEPLISAV™, Compared to Engerix-B® Vaccine","status":"COMPLETED","sponsor":"Dynavax Technologies Corporation","startDate":"2014-04","conditions":"Healthy","enrollment":8374},{"nctId":"NCT01282762","phase":"","title":"Long-Term Study on Safety and Immunogenicity of HEPLISAV™ and Engerix-B® in Adults With Chronic Kidney Disease","status":"COMPLETED","sponsor":"Dynavax Technologies Corporation","startDate":"2010-12","conditions":"Chronic Kidney Disease","enrollment":147},{"nctId":"NCT00435812","phase":"PHASE3","title":"Safety and Efficacy of HEPLISAV™ Hepatitis B Virus Vaccine Compared With Engerix-B® Vaccine","status":"COMPLETED","sponsor":"Dynavax Technologies Corporation","startDate":"2006-12","conditions":"Hepatitis B","enrollment":2428},{"nctId":"NCT01195246","phase":"PHASE3","title":"Safety and Immunogenicity of HEPLISAV™ a Hepatitis B Virus Vaccine in Adults on Hemodialysis","status":"COMPLETED","sponsor":"Dynavax Technologies Corporation","startDate":"2010-12","conditions":"End Stage Renal Disease","enrollment":155},{"nctId":"NCT01005407","phase":"PHASE3","title":"Safety and Immunogenicity Study of the Hepatitis B Virus (HBV) Vaccine, HEPLISAV Compared to Engerix-B Vaccine","status":"COMPLETED","sponsor":"Dynavax Technologies Corporation","startDate":"2010-02","conditions":"Healthy","enrollment":2452},{"nctId":"NCT01777295","phase":"PHASE2","title":"Development of Read-outs in Healthy, Hepatitis B Virus Naive Adults Vaccinated With the Hepatitis B Surface Antigen (HBsAg) in Combination With a GlaxoSmithKline (GSK) Biologicals' Adjuvant System","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-02-25","conditions":"Hepatitis B","enrollment":81},{"nctId":"NCT02126462","phase":"PHASE1","title":"Safety and Immunogenicity of Co-Administered Hookworm Vaccine Candidates Na-GST-1 and Na-APR-1 in Gabonese Adults","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2014-11","conditions":"Hookworm Infection, Hookworm Disease","enrollment":32},{"nctId":"NCT00698061","phase":"PHASE3","title":"Immunogenicity and Safety of an Adjuvanted HBV Vaccine Compared to Engerix™-B, in a Non-responder Population ≥ 15y","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"1999-11","conditions":"Hepatitis B","enrollment":145},{"nctId":"NCT00383591","phase":"PHASE3","title":"Comparison of Adjuvanted Hepatitis B Vaccine to Double Dose of Engerix™-B in Pre- /Haemodialysis Patients Aged ≥15 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2002-03","conditions":"Hepatitis B","enrollment":120},{"nctId":"NCT00697866","phase":"PHASE3","title":"Consistency of 3 Consecutive Lots of a Novel HBV Vaccine With Single-blind Safety Evaluation Using Engerix™-B as Control","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2000-08","conditions":"Hepatitis B","enrollment":951},{"nctId":"NCT00697749","phase":"PHASE3","title":"Immunogenicity and Safety of a Novel Adjuvanted HBV Vaccine in Healthy Volunteers Positive for the HLA-DQ2 Genotype","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"1999-04","conditions":"Hepatitis B","enrollment":230},{"nctId":"NCT00383227","phase":"PHASE3","title":"Comparison of Adjuvanted Hepatitis B Vaccine to Double Dose of Engerix™-B in Pre- /Haemodialysis Patients Aged ≥15 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"1999-12","conditions":"Hepatitis B","enrollment":165},{"nctId":"NCT00697554","phase":"PHASE3","title":"Immunogenicity and Safety of a Novel Adjuvanted HBV Vaccine in Pre-liver Transplant Patients 18 Years of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2000-01","conditions":"Hepatitis B","enrollment":93},{"nctId":"NCT02368327","phase":"NA","title":"Gene Expression Profiles in Muscle After Immunisation","status":"COMPLETED","sponsor":"University of Surrey","startDate":"2015-02","conditions":"Healthy","enrollment":45},{"nctId":"NCT00262002","phase":"PHASE2","title":"Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Infants","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2004-09","conditions":"Prevention of Meningococcal Disease","enrollment":601},{"nctId":"NCT00291954","phase":"PHASE3","title":"Compare the Immune Response & Safety Elicited by Henogen's Adjuvanted Hepatitis B Vaccine vs Aventis Pasteur MSD's Hepatitis B Vaccine in Pre-Dialysis & Dialysis Patients Who Did Not Respond to Previous Hepatitis B Vaccination","status":"COMPLETED","sponsor":"Henogen","startDate":"2006-03","conditions":"Hepatitis B","enrollment":257},{"nctId":"NCT00291980","phase":"PHASE3","title":"A Study to Compare the Immune Response and Safety Elicited by Henogen's Adjuvanted Hepatitis B Vaccine Compared to Aventis Pasteur MSD's Hepatitis B Vaccine in Pre-Dialysis and Dialysis Patients Who Responded to Previous Hepatitis B Vaccination But Lost Antibody.","status":"COMPLETED","sponsor":"Henogen","startDate":"2006-03","conditions":"Hepatitis B","enrollment":185},{"nctId":"NCT00291941","phase":"PHASE3","title":"A Study to Compare the Immune Response and Safety Elicited by Henogen's Adjuvanted Hepatitis B Vaccine Compared to GSK Biologicals Adjuvanted Hepatitis B Vaccine in Pre-Dialysis and Dialysis Patients Who Have Not Been Exposed to Hepatitis B.","status":"COMPLETED","sponsor":"Henogen","startDate":"2006-02","conditions":"Hepatitis B","enrollment":300},{"nctId":"NCT00480116","phase":"PHASE3","title":"Consistency Study of Three Lots of Henogen's Adjuvanted Hepatitis B Vaccine When Given in 0, 1 Month Schedule","status":"COMPLETED","sponsor":"Henogen","startDate":"2008-01","conditions":"Hepatitis B","enrollment":450},{"nctId":"NCT00699231","phase":"PHASE1","title":"Evaluation of Immunogenicity, Reactogenicity and Safety of HBV-MPL Vaccine vs Engerix™-B, in Haemodialysis Patients","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"1992-02","conditions":"Hepatitis B","enrollment":30},{"nctId":"NCT00697853","phase":"PHASE2","title":"Immunogenicity and Safety of GSK Biologicals' HBV-MPL Vaccine (2 Doses), and of Engerix™-B (3 Doses) in Healthy Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"1998-11","conditions":"Hepatitis B","enrollment":200},{"nctId":"NCT00698087","phase":"PHASE3","title":"Comparison of Safety, Immuno- and Reactogenicity of MPL-Adjuvanted Recombinant Hepatitis B Vaccine to That of Engerix™-B","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"1995-01","conditions":"Hepatitis B","enrollment":60},{"nctId":"NCT00697840","phase":"PHASE3","title":"Safety, Immunogenicity and Reactogenicity of Recombinant Hepatitis B Vaccine (Adjuvanted & New Formulation) and Engerix™-B","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"1995-06","conditions":"Hepatitis B","enrollment":150},{"nctId":"NCT00697931","phase":"PHASE3","title":"Immunogenicity and Reactogenicity of MPL Adjuvanted Recombinant Hepatitis B- Vaccine and Engerix™-B in Adult Non-Responders","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"1997-05","conditions":"Hepatitis B","enrollment":116},{"nctId":"NCT00697229","phase":"PHASE2","title":"Immunogenicity & Reactogenicity of HBV-MPL Vaccine and Engerix™-B in Healthy Adults Following 2 Different Schedules","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"1992-09","conditions":"Hepatitis B","enrollment":99},{"nctId":"NCT00696891","phase":"PHASE3","title":"Study Comparing Immunogenicity, Reactogenicity and Safety of GSK Bios' HBV-MPL Vaccine With That of Engerix™-B in Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"1997-06","conditions":"Hepatitis B","enrollment":380},{"nctId":"NCT00696917","phase":"PHASE3","title":"Safety and Immunogenicity of 3 Lots of GSK Biologicals' HBV-MPL Vaccine and Engerix™-B in Healthy Volunteers ≥ 15y","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"1999-04","conditions":"Hepatitis B","enrollment":1303},{"nctId":"NCT00697216","phase":"PHASE3","title":"Immunogenicity and Safety of GSK Biologicals' HBV-MPL Vaccine and Engerix™-B in Healthy Adults (15-40 Yrs).","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"1997-03","conditions":"Hepatitis B","enrollment":340},{"nctId":"NCT00452088","phase":"PHASE1","title":"A Phase Ib Trial of MSP 3 LSP in 1-2 Year Old Children in Burkina Faso","status":"UNKNOWN","sponsor":"African Malaria Network Trust","startDate":"2007-04","conditions":"Malaria","enrollment":45},{"nctId":"NCT00469651","phase":"PHASE1","title":"Phase Ib Trial of MSP3 LSP in Children in Tanzania","status":"UNKNOWN","sponsor":"African Malaria Network Trust","startDate":"2007-10","conditions":"Malaria","enrollment":45},{"nctId":"NCT00383383","phase":"PHASE3","title":"Comparison of Adjuvanted Hepatitis B Vaccine to Double Dose of Engerix™-B in Pre- /Haemodialysis Patients Aged ≥15 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"1999-12","conditions":"Hepatitis B","enrollment":141}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Hepatitis B adjuvanted vaccine","genericName":"Hepatitis B adjuvanted vaccine","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Biologic","firstApprovalDate":"","aiSummary":"This vaccine stimulates the immune system to produce antibodies and cellular immunity against hepatitis B virus by presenting hepatitis B surface antigen with an adjuvant that enhances the immune response. Used for Prevention of hepatitis B infection in adults, Prevention of hepatitis B infection in adolescents and children.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}